Similar articles

• Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.

  Friedman HS, Johnson SP, Colvin OM. Friedman HS, et al. Cancer Treat Res. 2002;112:199-209. doi: 10.1007/978-1-4615-1173-1_10. Cancer Treat Res. 2002. PMID: 12481718 Review. No abstract available.
• Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s).

  Sládek NE. Sládek NE. Cancer Treat Res. 2002;112:161-75. doi: 10.1007/978-1-4615-1173-1_8. Cancer Treat Res. 2002. PMID: 12481716 Review. No abstract available.
• Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance.

  Richardson ME, Siemann DW. Richardson ME, et al. Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):789-95. doi: 10.1016/s0360-3016(97)00469-0. Int J Radiat Oncol Biol Phys. 1997. PMID: 9369124
• Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.

  Chen G, Teicher BA, Frei E 3rd. Chen G, et al. Cancer Biochem Biophys. 1998 Jun;16(1-2):139-55. Cancer Biochem Biophys. 1998. PMID: 9923973
• Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.

  Parsons PG, Lean J, Kable EP, Favier D, Khoo SK, Hurst T, Holmes RS, Bellet AJ. Parsons PG, et al. Biochem Pharmacol. 1990 Dec 15;40(12):2641-9. doi: 10.1016/0006-2952(90)90582-6. Biochem Pharmacol. 1990. PMID: 2260988